文献速递血栓与止血

遗传性与获得性易栓症患者的血栓栓塞风险管理

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias.
PubMed 文献 · Blood · 2020-01-01

综述指出,遗传性易栓症对静脉血栓栓塞复发风险的预测价值有限,一过性诱发因素更为关键。获得性风险因素(如抗磷脂综合征、恶性肿瘤)需特殊管理。抗凝血酶缺乏或≥1个易栓缺陷可能是预后例外,但解读需个体化,治疗决策应权衡抗凝获益与风险及患者偏好。

要点

  • 一过性诱发因素对VTE复发风险的预测价值高于遗传性易栓症。
  • 获得性风险因素(抗磷脂综合征、恶性肿瘤)需调整抗凝选择或处理原发病。
  • 抗凝血酶缺乏或≥1个易栓缺陷可能是预后例外,但需个体化解读。

核心结论

  • 遗传性易栓症检测结果对VTE复发风险的预测价值有限,管理决策应基于个体化权衡抗凝获益与风险及患者偏好,而非算法路径。

研究设计与样本

  • 综述,通过多个案例小品文阐述遗传性易栓症检测结果的解读与临床应用。

主要发现

  • 一过性诱发风险因素的存在与否是VTE复发风险的最重要决定因素,其预后权重通常高于遗传性易栓症。
  • 获得性风险因素可能需要额外管理考虑,如抗磷脂抗体综合征影响抗凝选择,恶性肿瘤需处理新发疾病。
  • 抗凝血酶缺乏或≥1个易栓缺陷可能是预后评估的例外,但解读需细致。

关键数值与推荐

  • 抗凝血酶缺乏或存在≥1个易栓缺陷可能对预后评估有作用。

临床怎么用

  • 关注一过性获得性VTE风险因素,其预后权重通常高于遗传性易栓症。
  • 对抗磷脂抗体综合征患者考虑抗凝选择,对恶性肿瘤患者处理原发病。
  • 遗传性易栓症检测结果的解读需个体化,结合抗凝获益与风险及患者偏好决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While we are now able to diagnose inherited thrombophilias in a substantial number of patients with venous thromboembolism (VTE), the initial hope that their presence would inform recurrence risk and thus decisions on anticoagulation duration has largely been disappointing. Indeed, the presence or absence of transient provoking risk factors has proven to be the most important determinant of VTE recurrence risk. Thus, particular attention to transient acquired risk factors for VTE remains paramount, as they have generally been shown to carry more prognostic weight than inherited thrombophilias. The presence of other acquired risk factors may require additional management considerations, whether pertaining to anticoagulant choice, as in antiphospholipid antibody syndrome, or to addressing a new predisposing medical condition, as in malignancy. Antithrombin deficiency or the presence of ≥1 thrombophilic defect may be exceptions that can have a role in prognostication; however, as illustrated in this review through several case vignettes, interpretation and clinical application of the results of inherited thrombophilia testing is nuanced. We have chosen to focus on cases in which patients have been identified as having thrombophilic defects rather than the indications for undertaking testing in the first place or the extent of investigation. Management decisions in such cases ultimately hinge on individualized consideration of the benefits and risks of anticoagulation along with patient preference rather than on an algorithmic pathway based on thrombophilia status.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Moran J, Bauer KA. Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. Blood. 2020. PMID: 31917425. doi:10.1182/blood.2019000917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。